Beth Sherrill, RTI Health Solutions Global Head of Biometrics presented her research at the ASCO Breast Symposium on October 8, 2009.
The presentation on “Quality of Life and Quality-Adjusted Survival (Q-TWiST) in Patients Receiving Lapatinib Plus Letrozole as First-Line Therapy in Hormone Receptor Positive, HER2+ Metastatic Breast Cancer” provided evidence for treatment benefit beyond the usual efficacy parameters. Data came from a study in a population of postmenopausal women who may already have had treatment for breast cancer although they had not received previous therapy for advanced or metastatic disease.
“Our evaluation of treatments for metastatic breast cancer must include a quality-of-life assessment. The exciting news is that we are seeing newer treatments that delay progression without the deleterious side effects of early chemotherapies”, Ms. Sherrill said.
Key objectives of the exploratory analyses were as follows:
- Evaluate and compare the two treatment arms with respect to change in quality of life (QOL).
- Use the quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST) method to compare the treatment toxicity and time-dependent clinical outcomes simultaneously.
The 2009 meeting was the third annual Breast Cancer Symposium. With attendance at approximately 1500, this conference provided an opportunity for researchers from around the world to convene for in-depth discussions about the latest findings in breast cancer therapy.